Open Forum Infectious Diseases

EXPRESSION OF CONCERN

Expression of Concern: “Meta-analysis of Randomized

Trials of Ivermectin to Treat SARS-CoV-2 Infection”
Andrew Hill,1 Anna Garratt,2 Jacob Levi,3 Jonathan Falconer,4 Leah Ellis,5 Kaitlyn McCann,5 Victoria Pilkington,6 Ambar Qavi,5 Junzheng Wang,5 and
Hannah Wentzel5
1
Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK, 2Department of Infectious Diseases, University Hospital of Wales, Cardiff and Vale University Health Board,
UK, 3Department of Intensive Care, University College London Hospital, ULCH NHS Trust, London, UK, 4Department of Infectious Diseases, Chelsea and Westminster Hospital, Imperial NHS Trust,
London, UK, 5Faculty of Medicine, Imperial College London, London, UK, and 6Oxford University Clinical Academic Graduate School, University of Oxford, Oxford, UK

Open Forum Infectious Diseases, ofab358, https://doi. to Treat SARS-CoV-2 Infection” by Hill, et al. Subsequently, we
org/10.1093/ofid/ofab358 and the authors have learned that one of the studies on which

Downloaded from https://academic.oup.com/ofid/article/8/8/ofab394/6346765 by guest on 11 August 2021

Published: 06 July 2021 this analysis was based has been withdrawn due to fraudulent
On July 6, 2021, Open Forum Infectious Diseases published data. The authors will be submitting a revised version excluding
the article “Meta-analysis of Randomized Trials of Ivermectin this study, and the currently posted paper will be retracted.

Correspondence: Andrew Hill, PhD, Department of Pharmacology and Therapeutics,

University of Liverpool, 70 Pembroke Place, Liverpool L69 3GF, UK (microhaart@aol.com).
Open Forum Infectious Diseases®2021
© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases
Society of America. This is an Open Access article distributed under the terms of the Creative
Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/
licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the
work, in any medium, provided the original work is not altered or transformed in any way, and that
the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
https://doi.org/10.1093/ofid/ofab394

EXPRESSION OF CONCERN • ofid  • 1